SGMO - Earnings call transcript Q3 2020 | Sangamo Therapeutics, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Ladies and gentlemen, thank you for standing by and welcome to Sangamo Therapeutics Q3 2020 Webcast. At this time, all participants are in a listen-only mode. After the speaker presentation, there will be a question-and-answer session. [Operator Instructions] I would now like to hand the conference over to your host, Head of Corporate Communications, Aron Feingold. Madam, please go ahead.

Aron Feingold

you us thank and afternoon for today. joining Good Financial this several team, Officer; members me Lee, Sandy this Bettina the Jason are Chief on afternoon Chief Sung of Officer; leadership With Fontenot, of Interim Chief Research; call Sangamo Medical Chief Officer. Executive Mark Head Officer; McClung, Macrae, and Business including Cockroft, executive page. section Slides under the sangamo.com, at our in Events from the website, our corporate presentation can and Presentations and be Media found Investors current expectations. This forward-looking call regarding Sangamo’s includes statements to and royalties; the to These and collaboration are technologies our relating potential to collaborations therapies, the not to the such COVID-XX other our from timing treat plans royalties payments and manufacturing and regarding clinical to and for and building but resources the statements and for our data payments develop, expectations to to Sangamo therapies and and to financial demonstrate commercialize our historical patients; the our of strategy use earn and approvals potential receiving milestone certain develop and and our are evolving facts. statements cost plans our our include, performance these for clinical share statements pandemic; timing, to, limited of effects the the such not benefits availability regulatory that and and for R&D facilities, data timelines of opening to potential ability pipeline; diseases timelines conduct therapies; and certain obtain collaborators clinical trials we Actual results today. discuss what may substantially from differ

the file and statements risks under quarter except and undertake quarterly XX, the in required are we future as our specifically information, of for stated and we are measure. in no be applicable We believe measure date this call, is potential is results. this ended forward-looking our or in are law. considered of a this September XX-Q to performance not a documents to this are to duty such measure as made with certain discuss included Form comparable update This press non-GAAP available measure as are today The XXXX. on On and these report GAAP financial GAAP in measure. Exchange on future release, Securities understanding non-GAAP discussed to discussed of statements helpful performance isolation our on Commission, addition, comparable for financial past In that the call which substitute the today’s in and and not that meant we website. GAAP guarantees uncertainties our The is reconciliations subject

the Sandy would to call over CEO, Now, to Macrae. I our turn like

Sandy Macrae

to Thank you everyone and good afternoon call. on the

we advanced quarter, the our to continue This by evolving we as pandemic. on the adapt COVID-XX R&D conditions brought to activities

we are new and moving forward optimistic of dose our execution are trials. in We to initiate continue patients clinical to plans and

Pfizer This our patients. giroctocogene from cash with expect for million communicated previously Pfizer has triggered investigational in Biogen in research forward completed position. with event quarter also of Phase study the progressing with achievement expect or SB-XXX, they Sangamo, current we data $XX our receive AFFINE strengthening hemophilia-A for our the gene pivotal further that therapy XXXX. readout study milestone which a to We the AFFINE Pfizer collaboration the in our partners. and are activities and Novartis continuing ALS X our and our to move with associated fitelparvovec participant other projects work first dosed are research

first context believe candidate. in the September, two During of that investigators, patients monitoring cohort patients principal In dosed to highest meaningful the gene for safe disease. encouraging showing differentiated Alta the clinically potentially in Phase close the therapy the and the an tolerability, dose weeks X/X therapy patients. in rates data these and factor study update use support the X/X Investor gene from the in up STAR conditions Day, levels, with ST-XXX study regarding bleeding provided hemophilia-A Pfizer XX mid-September evaluating product in collaboration longest factor Fabry within and August COVID-XX, Pfizer Phase data Sangamo treated Sangamo

The now for is this study is An X. complete. ongoing of enrollment first cohort cohort

to We on study data of year. end the next share expect this by

During to first the Phase believe transplantation. track clinical CAR explore quarter, TXXXX for X/X potential CAR-T study Initiating next T allow study additional to we this the are cells received year. approvals of evaluating company study CAR-T in the regulatory to on the be kidney regulatory candidate, the or may initiate humans. cell us We in first-in-human reg reg we

genetically cell this provide proof-of-concept regs. T will using broader engineered We that therapy are for hopeful

allele Also nuclease we regs, another research this challenging earned testament a CXorfXX regulation our evaluate unmet to therapy on million R&D have It every activities diseases. this transplantation, technology payment selectively research momentum. in to I disease T-reg and to a the We that, disease additional need. support our details our With our In their Pfizer $X collaboration milestone finger accomplishments. recently ongoing completed this is ALS. Medical related the be look will provide turn with high Chief development associated who using modifying Pfizer therapies to our Bettina, gene medical to a with for repeats, continue receive further able diseases CNS will Officer, program, program. this impact expect call intend in associated from we demonstration quarter. yet work forward treatment clinical edited CAR-T on to remarkable closely develop quarter, with which to later We this to over versatile Pfizer Beyond way to technology a finger zinc zinc to may finger of target proteins including autoimmune we of allergenic are with designed our our zinc program,

Bettina Cockroft

afternoon. Good

endpoint fitelparvovec in challenges trial. giroctocogene or pleased global of pandemic. with patient arm programs. which study is first registrational annualized Phase be Sandy study is Factor AFFINE first As clinical and mentioned, in X in the while operations to our adapted and patients ABR partnered of our Therapy are rates, XX a provide AFFINE COVID-XX a open-label The compared evolving executing SB-XXX, wholly-owned acid will ABR evaluating or Pfizer to progress VIII Phase dosed severe the the following the multi-center X bleeding our hemophilia-A. bleeding collected for have SB-XXX This study, efficacy X And we our single moderately in months of replacement primary on to with treatment. in the safety will participants. in to severe study Phase the a baseline

shared follow-up VIII the these up meaningful followed year. need ALTA months, in the factor study data include The assess durability VIII for next following activity period the for the to activity level onset after XX Factor results over Both will to X-year analyzed single when infusion been steady the safety. without SB-XXX of X/X which further the few at prophylactic clinically kilogram Phase was dose and least patient. the genomes cohort at data of leads from be sustained the Pfizer present a weeks in tolerated. encouraged to XeXX event study patients in treated are in plan state by and updated longest have well level Pfizer throughout September, or X X secondary cohort high all a of dose Participants of XX months. efficacy generally per Each endpoints companies Factor for investor demonstrated the the further vector X that patients

and its in Phase gastrointestinal mutations Fabry of the in to due disease this includes and STAR dose therapy Fabry ST-XXX and follow-up function, of evaluating GbX to cohort in derivative will such an monitored dosed of levels. A years. is and monitoring The cardiac first years study disease. morbidities, STAR soluble X of accumulation will endpoints, Fabry two tolerability first patients impaired label followed XX open have of is patients evaluating allow challenging a enzyme, comprising the trial in the and GbX year The deficient the and ongoing. the and X/X infusion is gene clinical of substrates additional assessment older. symptoms lyso-GbX second study be study observation patients intravenous the in and participants α-Gal for α-Gal ranging A pain as and cohort and A classical which by candidate provide receive safety including a the expression Enrollment goal of gene, ST-XXX, long-term We is This a predictable ST-XXX multi-center resulting in single of symptoms. activity to durable X lyso-GbX. GLA Study renal the for the

expansion. expect efficacy We end across dose after GbX of to renal potential deliver morbidity evaluating tissue α-Gal ST-XXX the cardiac neuropathy. studies and Fabry data with reduced and ST-XXX towards function offers reduction that of and treatment substrate preserved the believe we that demonstrated We types. strong expression identified Preclinical for A will with XXXX a differentiated have cohort potentially full disease, be a shared

for a therapy, the ST-XXX intravenous does require one-time infusion preconditioning by As that gene regimen not patients. liver-directed delivered is any

oncology also application trial working the an mismatched study therapy, Throughout advances the Company STEADFAST clinical by closely to KITE-XXX to quarter, a end KITE, HLA-AX to Phase third transplantation. as it new a Gilead are receive evaluating initiate KITE in submit X/X KITE-XXX, cell that we XXXX. TXXXX evaluating approvals drug allogeneic the XXXX investigational clinical into CAR-T anti-CDXX We trial. therapy an of our and with a expects collaborator, reg first-in-human clinical CAR-T support the regulatory additional renal have continued in

of The The CAR-T STEADFAST cytokines supporting efficiently to both year. transplant disease in showed model. also the within receptor, cryopreserved. inflammatory undergo of to in Similar study our shown from patients inhibition modulation and and tolerated which undergo through month TXXXX safe be their in transplantation engineered will initiate reg CAR graft their other personalized a the transplantation T to of approaches, reg activate well to environment candidate. genetically the surgery cells will cell them the They engineering of subsequently allowing study T may and HLA-AX the the tolerogenic the and expect patients rejection a prevented will goal release a negative HLA-AX or HLA-AX procedure receive induce regs will upon rejection the HLA-AX CAR-T last data and the skin We recovery prevent immune Preclinical to rejection following isolated therapy renal through express and to to and Leukapheresis is be immune-mediated period studies. than prevention are that graft. The recognition the next presented of vivo engineered for antigen. TXXXX graft-versus-host cells chimeric antigen an study regs anti-inflammatory the localize drug

that expect result international this we process, therapy showed that countries of supports of of in immune excitement their immunosuppression. whole that cell scientific our X allowing cell will is the trials potentially enrollment. renal were study, of regulatory cell Recent transplant the very of restoration the and Sung transplant cell space plan show approach a the the to therapeutic As several financial for momentum promising is to patients now recipients of over is will gaining Sung? occur general detailed immune This levels dosing after burden regs normal publications months as and evaluate In across one a clinical community. immune a healthy useful in I minimization therapy overview and composition call turn study the a results. populations. in large particular, CAR-T an X-investigator regulatory led to safe patient gathering therapy out renal

Sung Lee

and Thank afternoon you, good Bettina everyone.

revenues million million reported Pfizer million achieved to financial share share per for results million for with for Pfizer. SB-XXX, was and Total in same loss pleased $XX.X a period $XX of the million CXorfXX quarter XXXX. same to net period compared candidate compared or $X.X our the $X the XXXX. We collaboration increase milestone million loss our $XX a XXXX. in of per for hemophilia-A partnered of We to attributable achieved net share $X.XX our for The milestone are a $X.XX third or to $XX.X a were primarily with

manufacturing facilities reflects period in Turning decrease non-GAAP million headcount were a in advancement which compensation clinical and stock-based were support These expenses, to XXXX. capabilities. supply operating exclude million operating compared for of to expansion our offset manufacturing by growth and expenses, our the expenses. pipeline partially increases to expense $XX.X $XX.X therapeutic the in expense, same and increase The

marketable balance Moving upfront we received securities. includes from and equivalents $XX the to Novartis. ended million million $XXX sheet, fee quarter This the payment with in license balance the cash, cash

to expect earlier. the will our Pfizer reach mentioned the current strong to $XX us milestone potential Hemophilia-A. quarter, of SB-XXX milestones, we payments the balance million important receive remains R&D filing Additionally, We including believe and sheet from the for BLA several allow for in

of expenses, $XXX $XXX our $XXX Turning remarks. full be million million will million. to Sandy in million to $XX estimated stock $XXX to closing non-GAAP for we estimated which exclude the guidance guidance, it compensation operating for are range range back turn expense of of I XXXX from now year million to to updating now estimated financial an

Sandy Macrae

Thank you, Sung.

clinical We and are adapt year. conditions momentum head as focused end the execution to towards building we the of on the and of COVID-XX

with progress pleased clinical and in our partner are our programs. We with operations

XXXX Our these into facility important advance Sangamo strong the us achieve operational pipeline. pivotal to X-year readout We to in Brisbane be the also half. milestones balance be continued therapy and in We end next and and next enrollment at year. X/X to and enables position Velban year in presentations and AFFINE R&D catalysts Pfizer’s a with believe data by AAV we this X a and year on remain our anticipate data cell several in sheet put Phase Phase for to have by X-year there expected are heading XXXX. of accomplishments We facilities believe a manufacturing Pfizer end track operational in expect year study Brisbane strong over

We XXXX. X/X has Sanofi same sickle expect the data year. We Operator, guided product the cell data first that study that that beta-thalassemia STAR forward first-in-human delivering data the follow-up and readout we commence at time. presenting study in milestones expect And the the questions. CAR-T anti-CDXX also year. for X/X is trial XXXX. the coming And continued end clinical disease occur on candidate, open from the of line readout the next Phase study study in KITE-XXX Phase to lastly, anticipate Phase We expects towards expected please XXXX. of the ST-XXX in X/X look in of allogeneic initiations will these reg CAR-T it’s KITE will enrollment

Operator

America. [Operator Geoff from of question first Bank Certainly. Meacham of the Instructions] And line with comes our

Geoff Meacham

is the I month congrats want first had for of on all your just the endpoint, obviously Hey, guys. on with looking lot of get the couple is to Thanks that on received. and a investor little a feedback I just just of BioMarin one CAR-T feedback conversations And then for question kind late. car to on to FDA us the relative a question bit is broader the XX more regs give progress. of rate is, the a that’s what the for wanted And subject second just context strategy on probability differentiating best study see bleed pipeline the hemophilia-A see, one that see the the versus what example, tumor you Thank maybe solid successes you for how for you. you cells? analyze liquid tumors the and and what of success, maybe

Sandy Macrae

Thank you for your questions.

On one with having to for all And Phase into how up see, with we landscape. Pfizer this program, The up I’m is will navigate right the their can what that known regular are X, certain that they pleased asset assured and hemophilia-A, be first so we they that limited conversations will enthusiasm we sounds, them. organization this around Pfizer and for in are with how the that you to know progress the their way regulatory the see their their down – can be CEO, authorities. because valuable

to CAR-T see to regs regs, real As is I’m Jason over regards expert talk strategy? to how this to you about area. CAR-T you going who And us pass Jason, your in can a

Jason Fontenot

the Thanks, question. Sandy. for thanks And

programs engineered space, and our So autoimmune are T-cells pointing start directed regulatory in these cancer. are the first, out and that for disease by off I’ll regulatory drugs T-cells, inflammatory

about bringing regulatory platform the forward. engineered that and excited really we’re So T-cell programs our we’re

we’ve progress study, the first-in-human and regs so our about received about and TXXXX. approvals excited far We’re CAR-T regulatory

with of be the engineered regulatory transplant in demonstration and ability engineer regs, And to our transplant. that rejection And further an study biology manufacture and will mismatch renal T-cells cell. of understanding We’re rapidly refining of of CAR-T will CAR-T we’re the goal our this and The prevention is T- test our our of in and TXXXX MHC leadership. of first-in-human field. advancing that the regs leaders be study developing this setting

what’s the antigen kidney recognize are T the setting that negative regs and So the graft will patient’s important And a our will CAR understand this and through efficacy for study about mentioned, regs. that test and multiple an drive suppress the Crohn’s Comerica And the indications disease. regs. be as is of graft is activation and the the inflammatory hypothesis to around will And immune by T engineered sclerosis and therapeutic programs receive important be therapy HLA-AX informing that we’re a the comprised is safety transplant. HLA-AX CAR-T and patient antigen enlarger where be of renal therapeutic to AX we’ll that accumulation And us study receptor such is that this pursuing in that this potential as the rejection going in this I of actively regs system. of autoimmune to positive CAR-T first and of

Geoff Meacham

Okay, great. Thank you.

Operator

Thank you.

line comes Maury Our of Jefferies. next question Raycroft from with the

Maury Raycroft

Thanks everyone. my the well. program I T as for had Hi, on reg one questions. taking

for more guess the anything process manufacturing Can led else about the be to that that talk pushing Is to can before what needs the on? study start to getting the study? comment study – more what to getting else XXXX? talk it And cell due have I you So can or you COVID started. autologous or you completed factors about starting

Sandy Macrae

for progress you your very we much thank Maury, mismatch. of are very the pleased for question, T reg with HLA-AX the

we the pleased for manufacturing. dis is the the where approval regulatory the the very call in impacting with is we will to hospitals, laboratories, from epic We’re COVID authorities, go

but general are that to with So forward able be a move impact, program. COVID confident we’ll there’s we this

Maury Raycroft

that is perspective figured standpoint, any can provide manufacturing is other all from and you there that? development And Alright. a on or process out

Jason Fontenot

how to which that XXXX reasons people of TxCell the regs, their is look from after different after was we T look acquired T-cells. of how understanding in One

And very made. with so they’ve the pleased progress we’re that

Maury Raycroft

Got it.

that Okay. was program, is I which wondering one, update sort if And under the any on timeline, then then program, as strategic that on you update other and guys question of just you Prion about program provide importance that talk status have, of had a that the on just can well. the I’m maybe radar, the

Sandy Macrae

what about of you them? hear talk we and can Prions me Jason, think

Jason Fontenot

is Sure, Sandy, The development. program you. preclinical in thank Prion

be we’ll the time. think, appropriate updates at forward I to So sharing looking

approaches both platform, in get our are partners power are another Institute example I deep platform. to think that that, our great by these forward. These Prion a partners of working Novartis. and Broad move we our Biogen the done they demonstrate program And as have is CNS, with talk a be both the we in of there our And in opportunity there has it to And have real we’re of the to similar taking group deep the what – is driven that the a see excited partnerships work expertise of to, with we this. Boston. and we’ll the about real some with initial in are

have technological that our to with expertise biological And expertise. match so we

Maury Raycroft

the it. for questions. for Got the Thanks Thank you perspective. taking

Jason Fontenot

Thank Maury. you,

Operator

line next the our Jim comes Burchinal And you. question of Thank Fargo. from with Wells

Yanan Zhu

is Hi, as Jim, It T product? a I autologous. it’s could – thanks the perhaps confirm for this a reg is you Because well. program for a on question taking some question. This my gene think additive whether Yanan on

it in the with the obviously is gene approach. So, a – audition HLA-AX put

renal dosing for persistence? And well. do product, for gene you How future this would the it’s the your persistence? comment you long-term can your And for of persistence? allogeneic you issue issue T-cells. CAR and you guess you do a program, Thanks. repeated would if whether as regulatory it’s for explore product, How see see the require of edited programs? transplant, I So on then allogeneic TXXXX,

Jason Fontenot

kidney for scientific start to we autologous and you as it’s be close one And So, transplant They understand out that that regs. so let of the biopsied which because path surface. can to the are we question. can renal implanted your very chosen have And questions. try lay me sensible thank the is with the advantages of effectiveness is the transplanted T of

and by cells be you either can we can required volunteers, or like look things allergenic forms an feature we which will allogeneics, of editing any regs. to to gradually can see develop by we treatment, important persistence So, regs studying to good as switch is that T from down be healthy T of up develop at and stem them other IPSCs donor would

cellular really regulatory very is options at of and to to are us as this we the have many as take those into edge cutting lucky So possible science areas.

Yanan Zhu

follow-up component? quick gene in there Got it. And a is a TXXXX editing

Sandy Macrae

an autologous and it TXXXX Jason, correct that. am doesn’t gene I on is have therefore editing form component.

Jason Fontenot

correct. but do is program, products. the a with we lentivirus of T ability have future for assets our that’s Yes, for CAR our that engineering obviously, Sangamo platform’s and to introduced at we platform, TXXXX, our one first the the regs genomic

Sandy Macrae

And and the why They merge brought take to sensible. needed reg platform T was editing and was that the brought we that experience the so TxCell Sangamo of they forward.

Yanan Zhu

component Got factor, it. origin any Then transcription is transcription maybe zinc or how there factors? the about factors, finger Thanks. think a just of do human, immunogenicity? think synthetic question how the about those wondering fully whether And we – should you transcription is in on it

Sandy Macrae

do Jason, that a have please? want go you on to

Jason Fontenot

Sure.

that zinc synthetic have human. protein sequence to that in fully we a that immunogenicity those suggest the the So, observations could desired direct expect we by to sequence, immunogenicity to-date finger human for made design the base components a specific the they fact we inherently should And order transcription a and transcription any is Obviously, in of lower. the factors be factors are are of genome to problem. be that all nature specific to haven’t

Yanan Zhu

taking you on much questions so progress. for congrats and our the Thank Great.

Sandy Macrae

Thank you very much.

Operator

you. from of Wang with next And Thank comes our the line Gena question Barclays.

Gena Wang

have questions. three my questions. taking for Thank you I

is X/X X not not data already quite Phase Now, is [indiscernible] this Phase Pfizer know I or Phase the tech from regarding did difference – to certainly transferred data the just have did given wondering, hemophilia-A, first experience X/X.

will to was predictability the one regarding is your In gene from X/X is dose X? you Phase the program. essence, X regarding regulation Pfizer, share So side And from the manufacturing Phase us X/X any and Program and now terms any Phase our understand then ALS, you of second X/X Phase zinc your finger hypothesis can help potential for manufacturing and Phase to thoughts thoughts regarding we us data transcription in protein also Pfizer can Partner transfer the data with question part. data

if can wondering order share that reduction biomarker regarding you have lyso-GbX is any showed is further like think from you will And initial you XX% So extend a already can optimal the baseline regarding thought enrolled cohort data determination what plasma cohort thoughts ERT. as program, this regarding the reference, color question efficiency the the your second the regarding that XX% the last optimal the dose? Fabry and be Avro a you study? the in cohort to the to R&D what Any you will determine versus reach you

Sandy Macrae

the I talk this Gena, progression to the I Pfizer – really study abstracts of may am in is hands announced were afraid Pfizer So in Phase disappoint and X they Alta today. ASH for announced the about with of my the you and their or answers. The

I that X, we Phase really be And until and to results. mustn’t ASH Phase see X see The and talking they results. will so so for wait convertibility between we guide you at X those Phase the about anything would

organization paid and is you produce for necessary all And milestone. product the that their CXorf, I research Pfizer they we the with them. pleased tell regards have transferred very can As into the

can study to Fabry? we I measure? Bettina, talk Fabry, looking pass to and will And what are what Bettina. am about regards As you going this for on

Bettina Cockroft

Absolutely.

question. So, for thank yes, you the

cohort I α-Gal is a predictable the So really due durable which as mentioned disease provide goal the deficient gene. expression the enzyme Fabry enrollment have dose to study and is in the enzyme, patients, the of two is we of first earlier, in ongoing. and A to GLA And mutations

of of in are we challenges and parameters. parameter in looking the at of some also be these But to you point substrates, Fabry. of GbX out, as important so morbidity one measuring lyso-GbX with this as the are we basis terms are the more patients going And

and first products, Remember, dose. are committee So, all goes this other on be we studies other will the of study to decisions be well optimal the along off monitoring of this move the data going course on and escalate, will is we making expansion. the the to Think tolerability with are monitoring data. to other a in data data have that and monitoring the start and safety is we the with in involved decisions forward we this that we that our be of as safety foremost, to of with our dose cohort from as ultimate totality that with we bring

Gena Wang

you. Okay, thank

Sandy Macrae

your very you Thank for much question.

Operator

Thank you.

Our next the question from Eric comes line of JPMorgan. Joseph with

Eric Joseph

XX to past wholly year, clinic – Hi, we months, get the partnering I be sense over thanks what are how I to platform programs the whether the the over amount one, of additional, owned taking of a well, Maybe fair leveraging strategic to guess a through XX relative have just next the perhaps we to coming largely seen there for question. am curious the a activities? Thanks. should thinking forward about potential up for

Jason Fontenot

for please. you, your this one like for Eric. you Mark, feels Thank question,

Mark McClung

Thanks Eric. question. the Hi, for

done, a that the we with they that candidates [indiscernible] the expanding cases, that of of targets most take weren’t is if CMS progressing but those that And us the look twofold. number the driver including have considering. they deals came the you we had really to at obviously and a end, us we in So towards come in otherwise [indiscernible] recently, some of couple to the

that patients a to of expertise really case become a they an I to Novartis and successful fully and programs are terms you being to to company as have as a at the is take of that heard clinic. reg resources are way second our well follow-on looked CAR-T our pipeline. is that extension partnerships potential sort at bringing they would and specific both products genomics criteria. are that as are case, assuming the the of those continually we the And of we clinic the fit take we well owned we type programs. forward But So of necessary in good example look looking really the intend wholly particular whether take think the medicine into We TXXXX as accelerate of a what advance in into which we intending to assets, for as those

Eric Joseph

Got are are to have for that disease there T walled development you addition it. states targets in essentially I reg, internal and or? guess or off certain prioritizing

Mark McClung

as CAR-T We in interest we Jason partners with with earlier. mean, look programs area got a we the and in Biogen I Naturally, and touched reg have obviously, at, are space disclosed heavily partnership CNS we that. we working are our taking with Novartis. autoimmune the not within our our about, have have on talked

And so, any decisions after let space, can don’t We are as believe for but choose we targets us important maybe made believe towards that we to on it really science the go there speak that you drive then yet. and that here to not that we things have develop particular we patients. in need

Eric Joseph

the Got for it. That’s helpful. question. Thanks taking

Mark McClung

Sure. Pleasure.

Operator

of Baral with comes And our Cowen. from line you. next Ritu Thank the question

Unidentified Analyst

for This you taking Thank on Ritu. guys. is question. Laila the Hi, for

me. from questions quick two Just

sites on the and then And them what contingent you. enrollment? program, clinical from a milestone collaboration next First, this for as Specifically, would STAR up Thank ALS a you I on for to trial is are quick the the study, Fabry what’s with steps reach, COVID color the are completed any on are the running? opportunity follow-up, have still be the next initiating helpful? that program? know Pfizer but the regarding cohort, impacts all a first the on you seeing and

Sandy Macrae

for question. you Thank your

would and monsoons on We we it’s again, call remarkable untouched is reiterate haven’t the transcription piece one and able haven’t be to would or to the of – ALS to program Pfizer one script, the other we and said I will science to of us I [indiscernible] us the a I forward them. suppress in of what Pfizer achieved leave the moved have commented say why come. when they it’s came what and requested

it it’s dreadful such hope as a gets as to because So let’s soon possible. let’s patients hope disease,

to Fabry disease, that you going Bettina refer who question? will I the For to am answer

Bettina Cockroft

Yes, and question. thank for you that

operations clinical we sites. I side, team hard working say, all very So have have excellent the on to on the clinical maintaining the an with relationship operations

we we study. sites, pandemic, footprint sites been the for to the initiate have qualify other also our as expand During able

worldwide, Of impact course, an than some COVID more others. has regions had

then two we things our going pandemic that dosing the are despite virtual perspective the the follow-up. with procedures stage of sure the put guide to going through confident first enrollment an in ultimately from really have assistants to patients to with make keep screening patients We operational with that, keep dosing this home the we sites enrollment the and helped place with visits where with together manage at have get the and us following can to and enrollment we and us

Unidentified Analyst

Got it.

for you color. thank Okay, the

Sandy Macrae

have Bettina case whether done am I patient well a should we taking first comes the clinical been have feel way treated But get to to very times. us this was that with responsibility I soon have And remarkable make do the We and team we COVID ready as that dose team not her they be which being there. we think pleased to navigated. are open. job as have in the to window up sure for doctors’

Unidentified Analyst

color. thank Got the for it. you

Operator

Thank you.

from comes question the next of line the with Truist. Our Germino Nicole

Nicole Germino

what it And for made everyone. does the in Fabry, and competition differentiated thanks determination? and tissue? promoter you evening, given the question. Good – better then that impact the or peers? is cardiac may how have Sangamo’s your On AAV about does ST-XXX renal And the that how than tested Hi, more space, get specifically taking my

Jason Fontenot

me So, let take one. that

from published, have to hemophilia-A. in and can’t supramaximal encouraging. dosing look going data in the We Fabry And it’s that people very shouldn’t are we what and results wait we data dosing we recently what with encouraged animal by to the dosed the on We patients the we effect. the But to and benefit telling show But achieved are to really able see are. we like. animal The prudent just both comment I let’s supramaximal am clinical AVX seen looks disease, and heart in until kidney.

guiding show the that escalation of is towards when the next clinical will phase year We results the are end completed. dose

Nicole Germino

much. so you Thank great. Okay,

Operator

you. Wang of with the our comes from And line question Thank Guggenheim next Evan Securities.

Evan Wang

kind know Thanks forward time requiring plan we data Any and going without generated share of will what’s programs across allo data the can CRISPR. you I points heme-A any and of data time CAR-T in Hi, the the one there and initial from allo picture seen that allo any prior far so heme-A of have thoughts – have and my all complete program, those patients take, and on specific for update guys. other from point two, the seen some I data, on to you require but we learnings trials? the the X/X. to given are some question. on especially ASH, Phase the have CAR-T allogene had program, early other on on taking at on the deaths data

Sandy Macrae

this heme-A So, pass to allo. let on to then comment Jason do the me and

future So been am is [indiscernible] data to accepted for for going demonstrate will factor. abstract for and no control the absent release allogeneic of bleeding the use conference hemophilia-A. will please? are Jason, about in There requirement they the can to of say to on Pfizer in ASH I continue to schedule of benefit and question, reduced an patients you to – that’s the events again talk

Jason Fontenot

Thank Sandy. Sure. you,

programs. the therapies that that excited referring KITE we seen their we year from next know oncology and have far therapies with believe as excited are having that our partnership allogeneic it data allo with have to their therapeutic the see expecting you on that into patients. studies to we KITE begin others we and to and to get consistent are are CD-XX real are believe we potential CAR-T these has I we support in therapy you Gilead CAR-T about and so allogeneic programs are KITE guided CAR-T So targeted the

Evan Wang

thank Okay, you.

Operator

now any Thank to further of turn the Communications, back Corporate call Aron I for over Feingold you. Head will remarks.

Aron Feingold

Thank to forward you once developments. keeping your today updated our for and on future again you joining for We us questions. look

Operator

you and today’s disconnect. gentlemen, for call. now you may this and concludes Thank participating conference Ladies

Sangamo Therapeutics (SGMO) 5 Nov 202020 Q3 Earnings call transcript